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 Joe Bilcke and colleagues investigated the cost-effectiveness of alternative 
delivery strategies for typhoid Vi-conjugate vaccine (TCV) in each of the 54 
countries eligible for financial support from Gavi, the Vaccine Alliance. In settings 
with high Salmonella enterica serovar Typhi incidence, an approach of routine 
vaccination of infants plus a catch-up campaign to the age of 15 years seems 
cost-effective and would reduce the number of cases in Zimbabwe by 68% over 
the next 10 years. 1 
 
Recently Zimbabwe conducted a one-off mass TCV vaccination campaign funded 
by Gavi targeting children 6 months to 15 years of age in communities affected 
by an on-going typhoid outbreak.2 This has been the first use of TCV and the first 
typhoid outbreak response vaccination campaign in Africa. The present and past 
outbreaks of cholera and typhoid are a terrible consequence of Zimbabwe’s 
failure to invest in and manage both its basic water and sanitation infrastructure 
and its health care system.3 In addition, dilapidated infrastructure, lack of 
diagnostics and drugs, brain drain, prohibitive user fees in health facilities and 
strikes by medical personnel have contributed to most recent outbreak of 
typhoid..  
FIEBRE (Febrile Illness Evaluation in a Broad Range of Endemicities, 
https://www.lshtm.ac.uk/research/centres-projects-groups/fiebre), a multi-
country study investigating the causes of fever in sub-Saharan Africa and 
southeast Asia has been enrolling adults and children presenting with fever at 
health facilities in Harare since June 2018. As part of the study, multiple 
diagnostic investigations are performed including; automated blood cultures, 
bacterial identification and drug susceptibility testing.  S. Typhi has been isolated 
from 23/133 and 38/183 blood culture in children and adults respectively.  Of 
the 61 S. Typhi isolates 54(88·5%) were multi-drug and 4 in 5 (80·3%) displayed 
diminished fluoroquinolone susceptibility. In the first three months after the 
vaccination campaign we observed a sharp decrease in one of the worst affected 
communitiesin the proportion of confirmed and suspected typhoid cases among 
children, but not adults. In this community, 23 (21·1%) of 109 blood cultures 
from children were positive for S Typhi before vaccination compared with zero 
of 24 after vaccination. By contrast, 18 (15·4%) of 117 blood cultures from 
adults were positive for S Typhi before vaccination compared with 20 (30·3%) of 
66 after vaccination. 
 
While the TCV vaccination campaign seems highly effective in reducing the 
typhoid incidence among children, a more comprehensive approach such as 
vaccination of adults and WASH (Water, sanitation and hygiene) interventions 
will be needed to halt this and future typhoid outbreaks once established.  
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